Managing residual risk in patients receiving statin therapy

View/ Open
File version
Version of Record (VoR)
Author(s)
Hamilton-Craig, Ian R
Griffith University Author(s)
Year published
2010
Metadata
Show full item recordAbstract
Patients receiving statin therapy to reduce total and low-density lipoprotein cholesterol (LDL-C) levels still have a residual risk of cardiovascular (CV) events. In most statin trials, CV events are reduced by about 30% compared with placebo, leaving about 70% residual risk of CV events that occur in spite of statin therapy.Patients receiving statin therapy to reduce total and low-density lipoprotein cholesterol (LDL-C) levels still have a residual risk of cardiovascular (CV) events. In most statin trials, CV events are reduced by about 30% compared with placebo, leaving about 70% residual risk of CV events that occur in spite of statin therapy.
View less >
View less >
Journal Title
Medical Journal of Australia
Volume
192
Issue
7
Copyright Statement
Hamilton-Craig IR. Managing residual risk in patients receiving statin therapy. Med J Aust 2010; 192 (7): 366-367. © Copyright 2010 The Medical Journal of Australia – reproduced with permission.
Subject
Biomedical and clinical sciences
Psychology